Abuso de cannabis na cefaleia em salvas - tratamento ou vício?
DOI:
https://doi.org/10.34119/bjhrv6n1-099Keywords:
cefaleia em salvas, Cannabis, canabidiol, abuso de substâncias ilícitasAbstract
Justificativa e Objetivos: A cefaleia em salvas (CS) é um tipo de dor de cabeça com uma prevalência de aproximadamente 0,1%, sendo considerada uma das mais intensas e incapacitantes dores conhecidas, conhecida também por algumas das vezes ser resistente ao uso de tratamentos convencionais. Mesmo dispondo de inúmeros tratamentos, a efetividade, tolerabilidade ou aderência a estes tratamentos são insuficientes. Sendo assim, muitas das pessoas que sofrem de CS, procuram tratamentos alternativos, abusando de drogas ilícitas (como a Cannabis) na tentativa de alívio da dor. Conteúdo: A busca foi realizada a partir da ferramenta de busca Pubmed dos artigos publicados nos últimos 10 anos, de 2012 até julho de 2022. O levantamento foi realizado utilizando os seguintes unitermos ou descritores: “Cannabis" e "Cluster Headache", "Cannabinoids" e "Cluster Headache", nas línguas: Português e Inglês. Foram encontrados estudos exploratórios transversais, pesquisas comparativas transversais e revisões bibliográficas. A busca resultou em 10 estudos e destes, foram selecionados 4 artigos. O critério de inclusão foi a presença de abuso de cannabis nos pacientes que sofrem de CS. Conclusão: Foi observado a presença do abuso de substâncias lícitas e ilícitas (Cannabis) dentre os pacientes que sofrem de CS devido à dor intensa e predisposição ao vício. Este estudo tenta evidenciar a necessidade da padronização do uso da Cannabis e de estudos de qualidade sobre o tema, na tentativa de ampliar conhecimento e reduzir o consumo irresponsável e ilegal pelas pessoas que sofrem de cefaleia em salvas.
References
Capobianco DJ and Dodick DW. Diagnosis and treatmentof cluster headache.Semin Neurol2006; 26: 242–259.
Cohen AS, Matharu MS and Goadsby PJ. Trigeminalautonomic cephalalgias: Current and future treatments. Headache 2007; 47: 969–980.
Goulle JP, Saussereau E and Lacroix C. Delta-9-tetrahy-drocannabinol pharmacokinetics [in French]. Ann PharmFr2008; 66: 232–244.
Elsohly MA and Slade D. Chemical constituents of mari-juana: The complex mixture of natural cannabinoids. LifeSci2005; 78: 539–548
Kudrow L. Physical and personality characteristics incluster headache. Headache 1974; 13: 197–202.
Levi R, Edman GV, Ekbom K, et al. Episodic clusterheadache. II: High tobacco and alcohol consumption inmales. Headache 1992; 32: 184–187.
Nappi G and Italian Cooperative Study Group on theEpidemiology of Cluster Headache (ICECH). Casecon-trol study on the epidemiology of cluster headache. I:Etiological factors and associated conditions. Neuroepidemiology 1995; 14: 123–127.
Manzoni GC. Cluster headache and lifestyle: Remarks ona population of 374 male patients. Cephalalgia 1999; 19:88–94.
Donnet A, Lanteri-Minet M, Guegan-Massardier E, et al. Sociêtê Française d’Etude des Migraines et Cêphalêes (SFEMC). Chronic cluster headache: A French clinical descriptive study. J Neurol Neurosurg Psychiatry. 2007; 78:1354-1358.
Aggarwal SK. Cannabinergic pain medicine: A concise clinical primer and survey of randomizedcontrolled trial results. Clin J Pain. 2013; 29:162-171.
Serrano A, Parsons LH. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther. 2011; 132:215-241.
Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: Physiology and pharmacology. Alcohol Alcohol. 2005; 40:2-14.
Maccarrone M, Gasperi V, Catani MV, et al. The endocannabinoid system and its relevance for nutrition. Annu Rev Nutr. 2010; 30:423-440.
Greco R, Gasperi V, Maccarrone M, Tassorelli C. The endocannabinoid system and migraine. Exp Neurol. 2010; 224:85-91.
Howlett AC. Efficacy in CB1 receptor-mediated signal transduction. Br J Pharmacol. 2004; 142:12091218.
Mailleux P, Vanderhaeghen JJ. Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci Lett. 1992; 148:173-176.
Moldrich G, Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides. 2000; 21:1735-1742.
Russo EB. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatmentresistant conditions? Neuro Endocrinol Lett. 2008; 29:192-200.
Russo EB. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatmentresistant conditions? Neuro Endocrinol Lett. 2004; 25:31-39.
Akerman S,Holland PR, Goadsby PJ.Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011; 12:570-584.
Greco R, Gasperi V, Sandrini G, et al. Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat. Cephalalgia. 2010; 30:296-302.
McGeeney BE. Cannabinoids and hallucinogens for headache. Headache. 2013; 53:447–458. doi: 10.1111/head.12025.
Mosek A, Dano M, Fainmesser Y, Hybloom Z. EHMTI-0136. Medical cannabis in the treatment of treatment-resistant, chronic cluster headache. A retrospective Rep. 2014;15:C46.
Kjellgren A, Henningsson H, Soussan C. Fascination and social togetherness—discussion about spice smoking on a Swedish Internet forum. Subst Abus. 2013; 7:191–198.
Soussan C, Kjellgren A. The flip side of “spice”: the adverse effects of synthetic cannabinoids as discussed on a Swedish Internet forum. NAD Nord. Stud. Alcohol Drugs. 2014; 31:207–219.
Soussan C, Kjellgren A. The users of novel psychoactive substances: online survey about their characteristics, attitudes and motivations. Int J Drug Policy. 2016; 32:77–84. doi: 10.1016/j.drugpo.2016.03.007.
Andersson M, Kjellgren A. The slippery slope of flubromazolam: experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum. NAD Nord Stud Alcohol Drugs. 2017:1–13.
Duxbury SW. Information creation on online drug forums: how drug use becomes moral on the margins of science. Curr Sociol 2015:1-18.
Braun V, Clarke V, Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. doi: 10.1191/1478088706qp063oa.
Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561–564.
Iversen L. Cannabis and the brain. Brain 2003; 126: 1252–1270.
May A, Bahra A, Büchel C, et al. Hypothalamic activation in cluster headache attacks. Lancet 1998; 352: 275–278.
Govare A, Leroux E. Licit and illicit drug use in cluster headache. Curr Pain Headache Rep 2014; 18: 413–413.
May A. Illicit drugs and cluster headache: An inevitable discussion. Cephalalgia 2012; 32: 1021–1022.
Andersson M, Persson M, Kjellgren A. Psychoactive substances as a last resort – a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduct J 2017; 14: 60–60.
Cuypers J, Altenkirch H and Bunge S. Personality pro-files in cluster headache and migraine. Headache 1981; 21:21–24.
de Domini P, Del Bene E, Gori-Savellini S, et al. Person-ality patterns of headache sufferers. Cephalalgia 1983;3(Suppl 1): 195–214.
Levi R, Edman GV, Ekbom K, et al. Episodic clusterheadache. I: Personality and some neuropsychologicalcharacteristics in male patients. Headache 1992; 32:119–125
Aggarwal SK, Carter GT, Sullivan MD, et al. Character-istics of patients with chronic pain accessing treatmentwith medical cannabis in Washington State. J Opioid Manag 2009; 5: 257–286
Elizabeth Leroux, Irina Taifas, et al. Use of cannabis among 139 cluster headache sufferers.Cephalalgia. 2013 Feb;33(3):208-13.doi: 10.1177/0333102412468669.
Martin Andersson, Mari Persson, Anette Kjellgren. Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduct J. 2017 Sep 5;14(1):60.doi: 10.1186/s12954-017-0186-6.
Ilse F de Coo, Willemijn C Naber, et al. Increased use of illicit drugs in a Dutch cluster headache population. Cephalalgia. 2019 Apr; 39(5): 626-634. doi:10.1177/0333102418804160.
Paolo Rossi, Marta Allena, et al. Illicit drug use in cluster headache patients and in the general population: a comparative cross-sectional survey. Cephalalgia. 2012 Oct;32(14):1031-40.doi: 10.1177/0333102412458190.
C Di Lorenzo, G Coppola, et al. The use of illicit drugs as self-medication in the treatment of cluster headache: Results from an Italian online survey. Cephalalgia. 2016 Feb;36(2):194-8.doi: 10.1177/0333102415583145. The international Classification of Headache disorders – 3rd ed. (2018) iCHd-3
